Literature DB >> 30743086

Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India.

M Netravathi1, Hari Krishna Bollampalli2, Maya Dattatraya Bhat3, Valakunja Harikrishna Ganaraja4, Shweta Prasad5, Anita Mahadevan6, Nitish Kamble7, Atchayaram Nalini8, Ravi Yadav9, Pramod Kumar Pal10, Parthasarthy Satishchandra11.   

Abstract

BACKGROUND: Neuromyelitis Optica (NMO) is an autoimmune astrocytopathic disorder due to AQP4 antibodies.
OBJECTIVES: To analyse clinical, neuroimaging features in NMO patients and assess the efficacy of various therapeutics.
METHODS: AQP4+ve NMO patients were diagnosed based on consensus diagnostic criteria.
RESULTS: 101 AQP4+ve NMO patients were seen with female (90) predominance. Adult population (71.3%) formed the larger group followed by pediatric (19.8%) and late-onset (8.9%). Myelopathy (36.2%) was most commonly seen followed by optic neuritis (19.1%), brainstem (17.1%), opticomyelopathy (16.1%), area postrema involvement (10.5%) and encephalopathy (1%). Encephalopathy and brainstem/cerebellar involvement were most common in pediatric population while opticomyelopathy was more common in late-onset patients. Hyperintensities of lower medulla was seen in 67.3% subjects and 49.5% had involvement of obex. Differential T2 hyperintensity of the long segment myelitis was found in 30.7%. Plasmapheresis was given in 71 subjects followed by maintenance therapy. Most of them showed significant improvement with EDSS score of 1 in 30.7%.
CONCLUSIONS: Clinical manifestations in AQP4+ve NMO patients may vary depending on the age at onset of illness. MRI features affecting cervicomedullary junction, obex, differential T2 hyperintensities of the spinal cord may form a useful diagnostic clue. Plasmapheresis is helpful in achieving remission along with immunomodulation.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervico-medullary junction; Mycophenolate mofetil; NMO; Neuromyelitis optica; Obex; Plasmapheresis; Rituximab

Mesh:

Substances:

Year:  2019        PMID: 30743086     DOI: 10.1016/j.msard.2019.01.032

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  4 in total

1.  Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease.

Authors:  Ivana Nieto-Aristizábal; Álvaro J Vivas; Pablo Ruiz-Montaño; Cristian C Aragón; Iván Posso-Osorio; Jairo Quiñones; Julián Alejandro Rivillas; Gabriel J Tobón
Journal:  Autoimmune Dis       Date:  2020-07-31

2.  Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation.

Authors:  Elham Khalilidehkordi; Laura Clarke; Simon Arnett; Wajih Bukhari; Sofia Jimenez Sanchez; Cullen O'Gorman; Jing Sun; Kerri M Prain; Mark Woodhall; Roger Silvestrini; Christine S Bundell; David Abernethy; Sandeep Bhuta; Stefan Blum; Mike Boggild; Karyn Boundy; Bruce J Brew; Matthew Brown; Wallace Brownlee; Helmut Butzkueven; William M Carroll; Celia Chen; Alan Coulthard; Russell C Dale; Chandi Das; Marzena J Fabis-Pedrini; David Fulcher; David Gillis; Simon Hawke; Robert Heard; Andrew P D Henderson; Saman Heshmat; Suzanne Hodgkinson; Trevor J Kilpatrick; John King; Chris Kneebone; Andrew J Kornberg; Jeannette Lechner-Scott; Ming-Wei Lin; Christopher Lynch; Richard A L Macdonell; Deborah F Mason; Pamela A McCombe; Jennifer Pereira; John D Pollard; Sudarshini Ramanathan; Stephen W Reddel; Cameron Shaw; Judith Spies; James Stankovich; Ian Sutton; Steve Vucic; Michael Walsh; Richard C Wong; Eppie M Yiu; Michael H Barnett; Allan G Kermode; Mark P Marriott; John Parratt; Mark Slee; Bruce V Taylor; Ernest Willoughby; Fabienne Brilot; Angela Vincent; Patrick Waters; Simon A Broadley
Journal:  Front Neurol       Date:  2020-06-16       Impact factor: 4.003

3.  Efficacy and Safety of Rituximab in Central Nervous System Demyelinating Disorders.

Authors:  Varsha A Patil; Saurabh N Kamat; Jamshed A Lalkaka; Bhim Singhal
Journal:  Ann Indian Acad Neurol       Date:  2021-06-22       Impact factor: 1.383

4.  Clinical Features, Gender Differences, Disease Course, and Outcome in Neuromyelitis Optica Spectrum Disorder.

Authors:  Nishita Singh; Rohit Bhatia; Prerna Bali; V Sreenivas; M V Padma; Vinay Goyal; Rohit Saxena; Deepa Dash; Ajay Garg; S Leve Joseph
Journal:  Ann Indian Acad Neurol       Date:  2020-01-06       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.